Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 6;12(2):e0149223.
doi: 10.1128/spectrum.01492-23. Epub 2024 Jan 12.

Risk factors for recognized and unrecognized SARS-CoV-2 infection: a seroepidemiologic analysis of the Prospective Urban Rural Epidemiology (PURE) study

Affiliations

Risk factors for recognized and unrecognized SARS-CoV-2 infection: a seroepidemiologic analysis of the Prospective Urban Rural Epidemiology (PURE) study

Darryl P Leong et al. Microbiol Spectr. .

Abstract

There are limited data on individual risk factors for SARS-CoV-2 infection (including unrecognized infection). In this seroepidemiologic substudy of an ongoing prospective cohort study of community-dwelling adults, participants were thoroughly characterized pre-pandemic. The SARS-CoV-2 infection was ascertained by serology. Among 8,719 participants from 11 high-, middle-, and low-income countries, 3,009 (35%) were seropositive for SARS-CoV-2. Characteristics independently associated with seropositivity were younger age (odds ratio, OR; 95% confidence interval, CI, per five-year increase: 0.95; 0.91-0.98) and body mass index >25 kg/m2 (OR, 95% CI: 1.16, 1.01-1.34). Smoking (as compared with never smoking, OR, 95% CI: 0.83, 0.70-0.97) and COVID-19 vaccination (OR, 95% CI: 0.70, 0.60-0.82) were associated with a reduced risk of seropositivity. Among seropositive participants, 83% were unaware of having been infected with SARS-CoV-2. Seropositivity and a lack of awareness of infection were more common in lower-income countries. The COVID-19 vaccination reduces the risk of SARS-CoV-2 infection (including recognized and unrecognized infections). Overweight or obesity is an independent risk factor for SARS-CoV-2 infection. Infection and lack of infection awareness are more common in lower-income countries.IMPORTANCEIn this large, international study, evidence of SARS-CoV-2 infection was obtained by testing blood specimens from 8,719 community-dwelling adults from 11 countries. The key findings are that (i) the large majority (83%) of community-dwelling adults from several high-, middle-, and low-income countries with blood test evidence of SARS-CoV-2 infection were unaware of this infection-especially in lower-income countries; and (ii) overweight/obesity predisposes to SARS-CoV-2 infection, while COVID-19 vaccination is associated with a reduced risk of SARS-CoV-2 infection. These observations are not attributable to other individual characteristics, highlighting the importance of the COVID-19 vaccination to prevent not only severe infection but possibly any infection. Further research is needed to understand the mechanisms by which overweight/obesity might increase the risk of SARS-CoV-2 infection.

Keywords: COVID-19; SARS-CoV-2; low-income countries; pandemic; seroepidemiology; transmission.

PubMed Disclaimer

Conflict of interest statement

M.L.D. has served on vaccine advisory boards for GSK, Sanofi, Pfizer, Janssen, Novavax, Medicago, Seqirus, and Merck and on Data Safety Monitoring Boards for CanSino Biologic and has received in-kind vaccine from Sanofi and funding from the World Health Organization, the Canadian Institutes of Health Research, and the Medical Research Council UK.

Figures

Fig 1
Fig 1
Bar graphs representing the proportion of 8,764 participants who were seropositive for SARS-CoV-2 (in blue) between November 2019 and September 2022, and the proportion of seropositive participants who were aware of SARS-CoV-2 infection (in red) stratified by country income level. Estimates were adjusted for the time from pandemic declaration to blood collection.
Fig 2
Fig 2
Scatterplot illustrating the relationship between country-level COVID-19 vaccination rates and SARS-CoV-2 seropositivity rates. Rates are adjusted for the time from pandemic declaration to the date of participants’ blood collection.

Similar articles

Cited by

References

    1. Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. 2021. Transmission of SARS-CoV-2: a review of viral, host, and environmental factors. Ann Intern Med 174:69–79. doi:10.7326/M20-5008 - DOI - PMC - PubMed
    1. Madewell ZJ, Yang Y, Longini IM, Halloran ME, Dean NE. 2021. Factors associated with household transmission of SARS-CoV-2: an updated systematic review and meta-analysis. JAMA Netw Open 4:e2122240. doi:10.1001/jamanetworkopen.2021.22240 - DOI - PMC - PubMed
    1. Ng OT, Marimuthu K, Koh V, Pang J, Linn KZ, Sun J, De Wang L, Chia WN, Tiu C, Chan M, Ling LM, Vasoo S, Abdad MY, Chia PY, Lee TH, Lin RJ, Sadarangani SP, Chen M-C, Said Z, Kurupatham L, Pung R, Wang L-F, Cook AR, Leo Y-S, Lee VJ. 2021. SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study. Lancet Infect Dis 21:333–343. doi:10.1016/S1473-3099(20)30833-1 - DOI - PMC - PubMed
    1. Levin AT, Owusu-Boaitey N, Pugh S, Fosdick BK, Zwi AB, Malani A, Soman S, Besançon L, Kashnitsky I, Ganesh S, McLaughlin A, Song G, Uhm R, Herrera-Esposito D, de Los Campos G, Peçanha Antonio ACP, Tadese EB, Meyerowitz-Katz G. 2022. Assessing the burden of COVID-19 in developing countries: systematic review, meta-analysis and public policy implications. BMJ Glob Health 7:e008477. doi:10.1136/bmjgh-2022-008477 - DOI - PMC - PubMed
    1. Corsi DJ, Subramanian SV, Chow CK, McKee M, Chifamba J, Dagenais G, Diaz R, Iqbal R, Kelishadi R, Kruger A, Lanas F, López-Jaramilo P, Mony P, Mohan V, Avezum A, Oguz A, Rahman MO, Rosengren A, Szuba A, Li W, Yusoff K, Yusufali A, Rangarajan S, Teo K, Yusuf S. 2013. Prospective urban rural epidemiology (PURE) study: baseline characteristics of the household sample and comparative analyses with national data in 17 countries. Am Heart J 166:636–646. doi:10.1016/j.ahj.2013.04.019 - DOI - PubMed

Substances